Sarepta Therapeutics, Inc. (NASDAQ:SRPT) EVP Sells $6,295,840.77 in Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) EVP Ryan Edward Brown sold 38,957 shares of the stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the sale, the executive vice president now directly owns 17,129 shares in the company, valued at approximately $2,768,217.69. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $157.96 on Friday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. The stock has a market cap of $14.93 billion, a price-to-earnings ratio of 1,436.00 and a beta of 0.96. The business has a 50 day simple moving average of $128.90 and a 200 day simple moving average of $121.71. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. During the same quarter in the prior year, the firm earned ($1.44) earnings per share. The firm’s revenue was up 63.1% compared to the same quarter last year. Analysts anticipate that Sarepta Therapeutics, Inc. will post 3.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. SVB Leerink increased their price target on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday. BMO Capital Markets lifted their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Monday. Needham & Company LLC reaffirmed a “buy” rating and set a $235.00 price target on shares of Sarepta Therapeutics in a research note on Thursday. Mizuho lifted their price objective on Sarepta Therapeutics from $145.00 to $179.00 and gave the stock a “buy” rating in a research report on Friday, May 17th. Finally, TheStreet upgraded shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $185.06.

Institutional Trading of Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SRPT. GAMMA Investing LLC grew its holdings in shares of Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares in the last quarter. Vanguard Capital Wealth Advisors grew its stake in shares of Sarepta Therapeutics by 3.8% during the 4th quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock worth $236,000 after acquiring an additional 90 shares in the last quarter. Riggs Asset Managment Co. Inc. raised its holdings in shares of Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares during the last quarter. WCM Investment Management LLC lifted its position in shares of Sarepta Therapeutics by 2.3% in the first quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock worth $813,000 after purchasing an additional 142 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC boosted its holdings in Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.